A new system for moving drugs to market

Issues in Science and Technology

Volumn 21, Issue 2, 2005, Pages 63-68

  Woosley, Raymond L ^a,b   Rice, Glenn ^c  

^a UNIVERSITY OF ARIZONA   (United States)

^b Critical Path Accelerate TI   (United States)

^c Bridge Pharmaceuticals Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG PRODUCTS; DRUG THERAPY; INVESTMENTS; RESEARCH AND DEVELOPMENT MANAGEMENT; RISK MANAGEMENT; SOCIETIES AND INSTITUTIONS;

DRUG DEVELOPMENT SYSTEMS; PRESCRIPTION DRUGS; SAFETY ASSESSMENTS;

DRUG PRODUCTS PLANTS;

EID: 12344307477     PISSN: 07485492     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (2)

1. Food and Drug Administration, Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products (Washington, D.C.: FDA, March 2004).
2. J. A. DiMasi, R. W. Hansen, and H. G. Grabowski, "The Price of Innovation: New Estimates of Drug Development Costs," Journal of Health Economics 22, no. 2 (March 2003): pp. 151-185.